Financial performance

Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US.

Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased by 4% at CER, driven by lower realised prices, partly offset by GLP-1 volume growth across geographies. Q1 2026 adjusted Obesity care sales increased by 22% at CER.

US Operations adjusted sales decreased by 11% at CER in Q1 2026, driven by lower realised prices, partly offset by volume growth across the Wegovy® product portfolio.

International Operations sales increased by 6% at CER in Q1 2026, driven by higher volumes.

Q1 2026 adjusted operating profit decreased by 6% at CER, while reported operating profit increased by 65% at CER, driven by a provision reversal related to the 340B Drug Pricing Program in the US.

Commercial highlights

Wegovy® pill was launched in the US on 5 January 2026, and for the week ending 17 April, total weekly prescriptions exceeded 200,000. Coupled with total prescriptions for Q1 2026 of around 1.3 million and now more than 2 million since launch, it marks the strongest-ever GLP-1 volume launch in the US. Q1 2026 sales for Wegovy® pill reached DKK 2,256 million, impacted by pre-launch pipeline fill with wholesalers and telehealth partners.

Pending regulatory decisions, the first Wegovy® pill launches outside the US are expected during the second half of 2026.

Pipeline progress

Within obesity, Wegovy® HD (injectable semaglutide 7.2 mg) was approved by the FDA in March and subsequently launched in the US on 7 April. In the STEP UP trial, Wegovy® HD provided 20.7% mean weight loss.

Within obesity, the zenagamtide AMAZE phase 3 programme was initiated.

Within diabetes, Awiqli®, the first-ever once-weekly basal insulin for type 2 diabetes, was approved by the FDA.

In sickle cell disease, etavopivat successfully met both co-primary endpoints in the HIBISCUS phase 3 trial.

Outlook

The 2026 outlook is raised, driven by increased expectations for GLP-1 product sales.

Adjusted sales growth for 2026, which excludes the 340B provision reversal, is now expected to be -4 to -12% at CER.

Adjusted operating profit growth, also excluding the 340B provision reversal, is now expected to be -4 to -12% at CER.

PROFIT AND LOSS DKK million	Q1 2026	Growth in DKK	Growth at CER

Net sales	96,823	24%	32%
Operating profit	59,618	54%	65%
Adjusted net sales1	70,063	(10%)	(4%)
Adjusted operating profit1	32,858	(15%)	(6%)

https://ml-eu.globenewswire.com/Resource/Download/2c05f453-837b-4311-9d2c-53303c9628d0